Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasting Clear all

Conditions: Bone Marrow Transplantation
Interventions: Fecal Microbiota Transplantation (FMT); Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Temporomandibular Disorders
Interventions: Chiropractic w/Activator & Self Care, Dental Care & Self Care, Sham AMCT, Self-Care Only Group; Device · Other
Lead sponsor: Palmer College of Chiropractic; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Coralville, Iowa • Davenport, Iowa • Iowa City, Iowa

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: TAK-831; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Nocturia
Interventions: Desmopressin Melt; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 64
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 54 more

Conditions: Healthy Volunteers
Interventions: MA-0211, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Levothyroxine Sodium Tablets 300 μg, Levothroid® Tablets 300 μg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Multi-drug Resistant Tuberculosis
Interventions: Pretomanid; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Metolazone Tablets 2.5 mg, Zaroloxyn® Tablets 2.5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: Zolpidem 10mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: ADME, Healthy
Interventions: napabucasin; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK2256294; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 9 Years to 12 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Chronic Urticaria
Interventions: Stress intervention; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Advanced Gastric Cancer
Interventions: Nivolumab, Ipilimumab, Relatlimab, BMS-986205, Rucaparib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Aurora, Colorado + 13 more

Conditions: Obesity, Colorectal Cancer, Microbial Colonization, Time Restricted Feeding, Stress, Psychological
Interventions: TRE, MBSR; Behavioral
Lead sponsor: Lisa Tussing-Humphreys; Other
Eligibility: 18 Years to 39 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Small Cell Lung Cancer
Interventions: Capmatinib, Nazartinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Clarithromycin, Biaxin®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Breast Cancer
Interventions: Saturated Fat Meal, Oleic Sunflower Oil Meal; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: Azithromycin, Zithromax®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: PreDiabetes
Interventions: Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Fecal Microbiota Transplantation After HSCT

Conservative Treatment of Patients With Temporomandibular Disorders

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg

Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Azithromycin 600 Mg Tablets, Fasting

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

Open Label Extension Study of HT-100 in Patients With DMD

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

Stress Intervention for Chronic Urticaria

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Clarithromycin 500 mg Tablets Under Fasting Conditions

Fast Food, Fatigue, and Inflammation

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions

Mechanisms for Activation of Beige Adipose Tissue in Humans